Syncona (SYNC) H2 2025 earnings summary

Executive summary

• Strategic update proposes a new investment policy to balance value creation and liquidity, returning cash to shareholders as private portfolio assets are realized, with a new private vehicle option for long-term investors.

• Portfolio maturing, with nearly 80% of value in clinical or commercial stage companies and two more expected to enter the clinic within 12 months.

• NAV per share declined 9.5% to 170.9p, mainly due to Autolus's valuation drop despite product launch and approval.

• Life science portfolio return of (17.0%), impacted by a 76% fall in Autolus share price and write-downs in Resolution and Biomodal, partially offset by uplifts from Beacon and Forcefield.

• Ten capital access milestones and three KVIPs delivered, with £310.6m raised by portfolio companies, including £175.5m from leading life science investors.

Financial highlights

• NAV of £1.05bn, 170.9p per share, down 9.5% year-over-year.

• Life science portfolio valued at £765.4m, a (17.0%) return year-over-year.

• £135.3m deployed into the life science portfolio, below guidance due to disciplined allocation and external capital raised.

• £43m deployed into share buybacks at a 37.4% discount to NAV, repurchasing 40m shares.

• Capital pool at year-end was £287.7m.

Outlook and guidance

• Focus remains on driving companies to key value inflection points (KVIPs) to maximize NAV growth through M&A and liquidity events.

• Portfolio well positioned to deliver value over the medium term, with 78.5% in clinical/commercial stage and two more expected to enter the clinic in 12 months.

• Board exploring options to accelerate cash returns and provide alternative opportunities for shareholders.

• Share buyback program paused pending further strategic announcements.